215 articles with NovoCure Ltd.
Novocure announced that Bill Doyle, Novocure’s Executive Chairman, will participate in the Jefferies 2019 Global Healthcare Conference on June 4, 2019, in New York City.
Shares of NovoCure are up more than 6% in premarket trading after the company announced it won regulatory approval for its mesothelioma treatment, NovoTTF-100L System.
FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma
Novocure (NASDAQ: NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved the NovoTTF-100L System in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM). NovoTTF-100L is a non-invasive, antimitotic cancer treatment that delivers Tumor Treating Fields to the region of the tumor.
Medicare Issues Proposed Local Coverage Determination that Provides Coverage of Optune® for Newly Diagnosed Glioblastoma
Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have issued a proposed local coverage determination (LCD) that provides coverage of Tumor Treating Fields, or Optune, for newly diagnosed glioblastoma (GBM)
Quarterly net revenues of $73.3 million, representing 41 percent growth versus the first quarter 2018 and 5 percent growth versus the fourth quarter 2018
Novocure Announces the International Journal of Radiation Oncology, Biology, Physics Publishes Data Demonstrating Higher Doses of Tumor Treating Fields Improved Survival of Newly Diagnosed Glioblastoma Patients
The study provides a definition for Tumor Treating Fields dose and sets a framework for future work on Tumor Treating Fields dosimetry and treatment planning
Novocure’s mission and values support its overarching patient-forward vision to make a difference in cancer
Inaugural AACR-Novocure Tumor Treating Fields Research Grant Recipients Announced at AACR Annual Meeting 2019
The recipients of the AACR-Novocure Tumor Treating Fields research grants were announced on April 2 at the American Association for Cancer Research Annual Meeting 2019 in Atlanta.
Novocure announced that it will report financial results for the first quarter 2019 on Thursday, May 2, 2019, before the U.S. financial markets open.
INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer
3/22/2019Biotech and pharma companies make appointments to strengthen executive teams, with moves at Sanofi, Forma, Orchard, CLSA, Sangamo, and more.
Novocure (NASDAQ: NVCR) today announced the retirement of Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development, effective May 1, 2019.
Novocure Announces 48 Presentations and a Symposium Session on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2019
A special symposium session, intended to highlight therapeutic advances, will focus on Tumor Treating Fields as a fourth modality in cancer treatment
Novocure announced that Wilco Groenhuysen, Novocure’s Chief Financial Officer, will participate in Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019, in New York City.
Three additional phase 3 clinical trials ongoing studying the use of Optune in brain metastases, non-small-cell lung cancer and pancreatic cancer
Novocure Announces Fourth Quarter and Full Year 2018 Operating Statistics, Preliminary Net Revenues and Provides Company Update
Full year 2018 preliminary net revenues of $248.0 million, representing annual growth of more than 40 percent compared to 2017
Novocure (NASDAQ: NVCR) will participate in the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 9, 2019, in San Francisco.
Novocure and the AACR Announce Four Inaugural Research Grants to Promote and Support Innovative Research on Tumor Treating Fields
The grants represent a joint effort to promote and support innovative research on Tumor Treating Fields.
Sub-Group Analysis of Novocure’s EF-14 Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Published in Journal of Neuro-Oncology Demonstrating More Time on Optune® Predicted Increased Survival
Novocure (NASDAQ:NVCR) announced today that the results of a retrospective post-hoc sub-group analysis of its EF-14 phase 3 pivotal trial in newly diagnosed glioblastoma (GBM) have been published in the Journal of Neuro-Oncology.
Novocure and Zai Lab Awarded Deal of the Year at 5th Annual BioCentury China Healthcare Summit in Shanghai, China
Novocure announced today that Novocure and Zai Lab have received the Deal of the Year Award from BayHelix at a ceremony during the 5th annual BioCentury China Healthcare Summit in Shanghai, China